• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

TACROLIMUS SAFE, EFFECTIVE

Fujisawa Inc, released data recently that supports the safety and efficacy of Protopic (tacrolimus ointment) 0.03 percent concentration in children with mild to moderate atopic dermatitis.

Related Videos
Related Content
Pediatric Melanoma in Review: Providing Considerations for Dermatologists
November 22nd 2024

Pediatric Melanoma in Review: Providing Considerations for Dermatologists

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
August 1st 2023

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Off-Treatment Remission Achieved with Dupilumab for Pediatric AD
November 4th 2024

Off-Treatment Remission Achieved with Dupilumab for Pediatric AD

The Cutaneous Connection
August 5th 2021

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

Combination of Abrocitinib and Dupilumab Effectively Treats Pediatric Atopic Dermatitis
October 17th 2024

Combination of Abrocitinib and Dupilumab Effectively Treats Pediatric Atopic Dermatitis

Psychosocial Impact of Alopecia Areata on Pediatric and Adolescent Patients
October 9th 2024

Psychosocial Impact of Alopecia Areata on Pediatric and Adolescent Patients

© 2024 MJH Life Sciences

All rights reserved.